Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Ronald S. Hill"'
Autor:
Caroline Constant, John D. Stroncek, Stephan Zeiter, Daniel Arens, Dirk Nehrbass, Dominic Gehweiler, Ursula Menzel, Lorin M. Benneker, Ronald S. Hill, Christoph E. Albers
Publikováno v:
Constant, Caroline; Stroncek, John D; Zeiter, Stephan; Arens, Daniel; Nehrbass, Dirk; Gehweiler, Dominic; Menzel, Ursula; Benneker, Lorin M; Hill, Ronald S; Albers, Christoph E (2022). Venous injection of a triphasic calcium-based implant in a sheep model of pulmonary embolism demonstrates minimal acute systemic effects. European spine journal, 31(10), pp. 2812-2821. Springer 10.1007/s00586-022-07303-x
Purpose Implant leakage is the most common complication of vertebral augmentation. Alternative injectable materials must demonstrate intravascular safety comparable to or better than polymethyl methacrylate (PMMA). This study assessed the systemic ef
Autor:
Jonathan L. Shaul, R R Cheng, Ronald S. Hill, Harry K. Genant, B Huber, J Stroncek, D C Lee, D Favell, Tony M. Keaveny, Klaus Engelke, Mary L. Bouxsein, James G. Howe
Publikováno v:
Osteoporosis International
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, vol 31, iss 5
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, vol 31, iss 5
Summary This first-in-human study of AGN1 LOEP demonstrated that this minimally-invasive treatment durably increased aBMD in femurs of osteoporotic postmenopausal women. AGN1 resorption was coupled with new bone formation by 12 weeks and that new bon
Autor:
Dominique Favell, Jonathan L. Shaul, James G. Howe, Ronald S. Hill, Mary L. Bouxsein, Bryan Huber, John D. Stroncek
Publikováno v:
Journal of Orthopaedic Research
Current pharmaceutical therapies can reduce hip fractures by up to 50%, but compliance to treatment is low and therapies take up to 18 months to reduce risk. Thus, alternative or complementary approaches to reduce the risk of hip fracture are needed.
Autor:
Ronald S. Hill, Jonathan L. Shaul, David B. Burr, James G. Howe, Mary L. Bouxsein, Annemarie K. Tilton
Publikováno v:
Bone. 154:116246
Background Fractures secondary to osteoporosis, particularly those of the hip and spine, are a major public health concern with high social and economic costs. The Local Osteo-Enhancement Procedure (LOEP) is an approach intended to strengthen skeleta
Publikováno v:
Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society. 13(3)
A novel injectable scaffolding matrix (E-Matrix) has been developed to accelerate wound healing in diabetic foot ulcers. This porcine collagen-derived matrix is designed to mimic tertiary embryonic connective tissue and to stimulate fetal wound repai
Publikováno v:
Diabetes. 40(8)
Recombinant tissue consisting of adult ductal epithelium isolated from pancreas and fetal mesenchyme was transplanted subcutaneously in the inguinal region of nude mice or epididymal fat pads of rats with a tissue chamber device for short-term (8-day
Publikováno v:
Diabetes. 36(4)
With an SV40-transformed hamster β-cell line (HIT cells) as a model system, we tested the hypothesis that a rise in cAMP levels potentiates insulin release by an effect on the cytosolic free-Ca2+ concentration ([Ca2+])i. Intracellular cAMP levels we
Autor:
A. E. Boyd, Ronald S. Hill
Publikováno v:
Diabetes. 34(2)
A perifusion system for the study of insulin secretory dynamics of a clonal, Simian virus 40-transformed hamster pancreatic beta cell line (HIT cells) is described. After a change from glucose-free to higher glucose levels in the perifusate, insulin
Publikováno v:
Diabetes. 38(7)
With a glucose-responsive (β-cell line (HIT cells), we tested the hypothesis that the cytosolic free Ca2+ level ([Ca2+],) is an intracellular signal through which a rise in cyclic AMP (cAMP) levels is transmitted to potentiate glucose-stimulated ins